The drug name and manufacturer of domestic axitinib

Domestic axitinib (Axitinib) currently has no domestic version that has been officially approved for marketing, so the original drugs circulating in the market are mainly imported. Axitinib, originally developed by Pfizer, is an oral small molecule angiogenesis inhibitor, mainly suitable for second-line treatment of patients with advanced renal cell carcinoma. The drug has been approved for marketing in China in the early years and has been included in the national medical insurance directory. Domestic patients can purchase the original axitinib drug through regular hospitals or pharmacies.

Although axitinib has been on the market in China for many years, no domestic generic drugs have been officially launched yet, and most domestic hospitals still use the imported version from Pfizer. According to market feedback, the price of imported original research drugs is approximately 4,000 yuan per box, and the specification is 5mg*60 tablets. After being included in medical insurance, the actual out-of-pocket expenses will vary according to the medical insurance policy of the patient's location. It is recommended that patients consult the pharmacy department or medical insurance office of the hospital where they are treated to learn about the latest reimbursement policies and self-pay ratios.

For patients who are relatively price-sensitive, some people choose to purchase generic axitinib through overseas channels. Currently, the more common ones on the market are the Indian and Lao versions of generic drugs. The prices of these versions are relatively more affordable, with a box usually costing several hundred yuan. Generic drugs are basically the same as the original drugs in terms of ingredients, dosage, and usage, and their efficacy is relatively close. Therefore, they have become an important alternative for some patients to reduce the burden of treatment.

Overall, although no domestically produced axitinib has been approved for marketing in China, patients can obtain treatment more conveniently in China because the original drug has been included in medical insurance. For patients with limited financial ability or whose medical insurance cannot fully cover them, they can also consider legal and compliant channels to obtain lower-priced overseas generic drugs. Before taking medication, it is still recommended that patients make choices under the guidance of a professional doctor to ensure the safety and effectiveness of the medication.

Reference materials:https://en.wikipedia.org/wiki/Axitinib